Text Size

Sickle Cell Anemia in an Arab Bedouin Village in the Northern Israel

This study has been completed.
Sponsor:
Information provided by:
HaEmek Medical Center, Israel
ClinicalTrials.gov Identifier:
NCT00481039
First received: May 31, 2007
Last updated: September 3, 2009
Last verified: September 2009
History of Changes
  Purpose

Sickle cell anemia and sickle cell thalassemia are frequent diseases among the israeli arab population. The purpose of this study is to assess the clinical characteristics of the patients in one arab village and the laboratory characteristics in the carriers of this gene based in the screening for pregnant women that is carried out in the population of northern Israel.

The results can be useful in order to institute universal screening for sickle cell anemia in northern Israel.


Condition Intervention
Sickle Cell Disease
 Procedure: Medical history and basic laboratory analysis

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Retrospective
Official Title: Sickle Cell Anemia in an Arab Bedouin Village in the Northern Israel- An Observational Study

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by HaEmek Medical Center, Israel:

Estimated Enrollment: 300
Study Start Date: May 2007
Study Completion Date: December 2008
Primary Completion Date: December 2008 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
1
Patients diagnosed as having abnormal hemoglobin like hemoglobin S and thalassemia in a bedouin village
 Procedure: Medical history and basic laboratory analysis
Medical history and basic laboratory analysis

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

All the patients diagnosed with abnormal hemoglobin in the bedouin arab village

Criteria

Inclusion Criteria:

  • All the patients that were diagnosed as having sickle cell disease in the specific village and all the population screened for hemoglobinopathies in the same location
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00481039

Locations
Israel
Pediatric Hematology Unit - HaEmek Medical Center
Afula, Israel, 18101
Sponsors and Collaborators
HaEmek Medical Center, Israel
Investigators
Study Director: Ariel Koren, MD Pediatric Hematology Unit, Ha'Emek Medical Center
Study Chair: luci Zalman, Phd Hematology Laboratory - HaEmek Medical Center
Principal Investigator: Tania Flaishman, Student Pediatric Dpt B - Ha'Emek Medical Center
  More Information

No publications provided

Responsible Party: Dr Koren Ariel, Pediatric Hematology Unit - Ha'Emek Medical Center
ClinicalTrials.gov Identifier: NCT00481039     History of Changes
Other Study ID Numbers: 5311006.EMC
Study First Received: May 31, 2007
Last Updated: September 3, 2009
Health Authority: Israel: Ministry of Health

Keywords provided by HaEmek Medical Center, Israel:
Sickle cell disease
Sickle cell thalassemia
Population screening

Additional relevant MeSH terms:
Anemia, Sickle Cell
Anemia, Hemolytic, Congenital
Anemia, Hemolytic
Anemia
 Hematologic Diseases
Hemoglobinopathies
Genetic Diseases, Inborn

ClinicalTrials.gov processed this record on June 17, 2013